{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:43:19Z","timestamp":1772574199174,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772824"],"award-info":[{"award-number":["81772824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["2017-8"],"award-info":[{"award-number":["2017-8"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10549-019-05483-7","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T14:02:29Z","timestamp":1574690549000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1\/2-negative breast cancer patients"],"prefix":"10.1007","volume":"179","author":[{"given":"Yifan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benyao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-3839","authenticated-orcid":false,"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"2","key":"5483_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2006","unstructured":"Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T et al (2006) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165\u2013167","journal-title":"Nat Genet"},{"issue":"6","key":"5483_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","volume":"22","author":"B Xia","year":"2006","unstructured":"Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719\u2013729","journal-title":"Mol Cell"},{"issue":"7","key":"5483_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1158\/1541-7786.MCR-09-0123","volume":"7","author":"F Zhang","year":"2009","unstructured":"Zhang F, Fan Q, Ren K, Andreassen PR (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7(7):1110","journal-title":"Mol Cancer Res"},{"issue":"6","key":"5483_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cub.2009.02.018","volume":"19","author":"F Zhang","year":"2009","unstructured":"Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19(6):524\u2013529","journal-title":"Curr Biol"},{"issue":"17","key":"5483_CR5","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1073\/pnas.0811159106","volume":"106","author":"SM Sy","year":"2009","unstructured":"Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106(17):7155\u20137160","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7133","key":"5483_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature05609","volume":"446","author":"H Erkko","year":"2007","unstructured":"Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316\u2013319","journal-title":"Nature"},{"issue":"14","key":"5483_CR7","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-08-0210","volume":"14","author":"H Erkko","year":"2008","unstructured":"Erkko H, Dowty JG, Nikkila J, Syrjakoski K, Mannermaa A, Pylkas K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A et al (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14(14):4667\u20134671","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5483_CR8","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, Blomqvist C, Nevanlinna H (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15(9):3214\u20133222","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5483_CR9","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/bcr3392","volume":"15","author":"ZL Teo","year":"2013","unstructured":"Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T, Dowty JG, Hopper JL, Winship I, Goldgar DE et al (2013) Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res 15(1):R17","journal-title":"Breast Cancer Res"},{"issue":"16","key":"5483_CR10","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1073\/pnas.0701724104","volume":"104","author":"M Tischkowitz","year":"2007","unstructured":"Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA et al (2007) Analysis of PALB2\/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104(16):6788\u20136793","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"5483_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","volume":"16","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Klu\u017aniak W, Huzarski T, Woko\u0142orczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, D\u0119bniak T, G\u00f3rski B et al (2015) Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 16(6):638\u2013644","journal-title":"Lancet Oncol"},{"issue":"6","key":"5483_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ijc.32184","volume":"145","author":"M Deng","year":"2019","unstructured":"Deng M, Chen HH, Zhu X, Luo M, Zhang K, Xu CJ, Hu KM, Cheng P, Zhou JJ, Zheng S et al (2019) Prevalence and clinical outcomes of germline mutations in BRCA1\/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer 145(6):1517\u20131528","journal-title":"Int J Cancer"},{"issue":"3","key":"5483_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10549-017-4425-z","volume":"166","author":"K Zhang","year":"2017","unstructured":"Zhang K, Zhou J, Zhu X, Luo M, Xu C, Yu J, Deng M, Zheng S, Chen Y (2017) Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Breast Cancer Res Treat 166(3):865\u2013873","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5483_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylk\u00e4s K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497\u2013506","journal-title":"N Engl J Med"},{"issue":"6","key":"5483_CR15","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/bcr2796","volume":"12","author":"MC Southey","year":"2010","unstructured":"Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I et al (2010) A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 12(6):R109","journal-title":"Breast Cancer Res"},{"issue":"23","key":"5483_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"9","key":"5483_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196","journal-title":"JAMA Oncol"},{"issue":"3","key":"5483_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-008-0036-z","volume":"114","author":"AY Cao","year":"2009","unstructured":"Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH et al (2009) The prevalence of PALB2 germline mutations in BRCA1\/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114(3):457\u2013462","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"5483_CR19","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, Wang L, Ouyang T, Li J, Wang T et al (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 23(20):6113","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5483_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A et al (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19(1):4\u201323","journal-title":"J Mol Diagn"},{"key":"5483_CR21","unstructured":"Daly MB PR, Berry M et al (2019) NCCN Clinical practice guidelines in oncology. In: Genetic\/familial high-risk assessment: breast and ovarian version 3. Accessed 17 Jan, 2019"},{"key":"5483_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917","journal-title":"Nature"},{"key":"5483_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913","journal-title":"Nature"},{"issue":"9737","key":"5483_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England) 376(9737):235\u2013244","journal-title":"Lancet (London, England)"},{"issue":"10","key":"5483_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nsmb.1915","volume":"17","author":"R Buisson","year":"2010","unstructured":"Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17(10):1247\u20131254","journal-title":"Nat Struct Mol Biol"},{"issue":"30","key":"5483_CR26","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ et al (2017) Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 35(30):3382\u20133390","journal-title":"J Clin Oncol"},{"key":"5483_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2015","unstructured":"Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, Vaccari EM, Bissonnette J, Booker JK, Cremona ML et al (2015) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18:823","journal-title":"Genet Med"},{"issue":"1","key":"5483_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ijc.30428","volume":"140","author":"C Kraus","year":"2017","unstructured":"Kraus C, Hoyer J, Vasileiou G, Wunderle M, Lux MP, Fasching PA, Krumbiegel M, Uebe S, Reuter M, Beckmann MW et al (2017) Gene panel sequencing in familial breast\/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1\/2. Int J Cancer 140(1):95\u2013102","journal-title":"Int J Cancer"},{"issue":"5924","key":"5483_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","volume":"324","author":"S Jones","year":"2009","unstructured":"Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC-H, Palmisano E, Brune K, Jaffee EM et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924):217","journal-title":"Science"},{"issue":"44","key":"5483_CR30","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A et al (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44):18032","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"5483_CR31","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/carcin\/bgp218","volume":"30","author":"MJ Garcia","year":"2009","unstructured":"Garcia MJ, Fernandez V, Osorio A, Barroso A, Fernandez F, Urioste M, Benitez J (2009) Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1\/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 30(11):1898\u20131902","journal-title":"Carcinogenesis"},{"issue":"2","key":"5483_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-010-1290-4","volume":"126","author":"N Bogdanova","year":"2011","unstructured":"Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, Christiansen H, Rave-Fr\u00e4nk M, D\u00f6rk T, Imyanitov EN (2011) PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat 126(2):545\u2013550","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5483_CR33","doi-asserted-by":"publisher","first-page":"E2176","DOI":"10.1002\/humu.21478","volume":"32","author":"H Hellebrand","year":"2011","unstructured":"Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M et al (2011) Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat 32(6):E2176\u2013E2188","journal-title":"Hum Mutat"},{"issue":"4","key":"5483_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10689-010-9382-1","volume":"9","author":"C Balia","year":"2010","unstructured":"Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA (2010) PALB2: a novel inactivating mutation in a Italian breast cancer family. Fam Cancer 9(4):531\u2013536","journal-title":"Fam Cancer"},{"issue":"2","key":"5483_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.canlet.2015.01.022","volume":"359","author":"AP Sokolenko","year":"2015","unstructured":"Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, Iyevleva AG, Mitiushkina NV, Zaitseva OA, Yatsuk OS, Tiurin VI, Strelkova TN, Togo AV et al (2015) Candidate gene analysis of BRCA1\/2 mutation-negative high-risk Russian breast cancer patients. Cancer Lett 359(2):259\u2013261","journal-title":"Cancer Lett"},{"issue":"2","key":"5483_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10689-009-9295-z","volume":"9","author":"L Papi","year":"2010","unstructured":"Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D (2010) A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer 9(2):181\u2013185","journal-title":"Fam Cancer"},{"issue":"1","key":"5483_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-016-4038-y","volume":"161","author":"O Moran","year":"2017","unstructured":"Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, Akbari MR, Kotsopoulos J (2017) Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Breast Cancer Res Treat 161(1):135\u2013142","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5483_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-016-4034-2","volume":"161","author":"H Kim","year":"2017","unstructured":"Kim H, Cho DY, Choi DH, Oh M, Shin I, Park W, Huh SJ, Nam SJ, Lee JE, Kim SW (2017) Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Res Treat 161(1):95\u2013102","journal-title":"Breast Cancer Res Treat"},{"key":"5483_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ng1947","volume":"39","author":"S Reid","year":"2006","unstructured":"Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M et al (2006) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162","journal-title":"Nat Genet"},{"issue":"4","key":"5483_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33(4):304\u2013311","journal-title":"J Clin Oncol"},{"key":"5483_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/gim.2014.153","volume":"17","author":"DB Zhen","year":"2014","unstructured":"Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ et al (2014) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569","journal-title":"Genet Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05483-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T01:02:32Z","timestamp":1606179752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5483"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05483-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}